Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
THBS1
REST API REST API
Homo sapiens
THBS1 is differentially expressed in 408 experiments: 193 organism parts: lung, placenta, ... (191 more);, 285 disease states: normal, glioblastoma, ... (283 more);, 153 cell types 546 cell lines 56 compound treatments and 87 other conditions.
Synonyms TSP1, TSP, THBS-1, THBS, TSP-1
Orthologs Q5VH52_CIOIN (Ciona intestinalis)   THBS1 (Bos taurus)   Tsp (Drosophila melanogaster)   THBS1 (2 of 2) (Danio rerio)   thbs1 (Danio rerio)   Thbs1 (Mus musculus)   THBS1 (Gallus gallus)   thbs1 (Xenopus laevis)   THBS1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cell migration, stored secretory granule, protein binding, positive regulation of translation, extracellular space, heparin binding, negative regulation of apoptosis, eukaryotic cell surface binding, structural molecule activity, cell cycle arrest, extracellular region, blood coagulation, anti-apoptosis, response to hypoxia, positive regulation of transforming growth factor beta receptor signaling pathway, external side of plasma membrane, activation of MAPK activity, negative regulation of fibroblast growth factor receptor signaling pathway, transforming growth factor beta binding, identical protein binding, cell adhesion, induction of apoptosis, immune response, response to drug, integrin binding, cellular response to heat, extracellular matrix, calcium ion binding, peptide cross-linking, negative regulation of caspase activity, negative regulation of focal adhesion assembly, fibroblast growth factor 2 binding, positive regulation of cell-substrate adhesion, response to magnesium ion, negative regulation of fibrinolysis, negative regulation of blood vessel endothelial cell migration, platelet degranulation, growth plate cartilage development, negative regulation of angiogenesis, laminin binding, response to calcium ion, response to progesterone stimulus, fibrinogen complex, extracellular matrix binding, positive regulation of endothelial cell migration, positive regulation of cell migration, negative regulation of endothelial cell migration, phosphatidylserine binding, negative regulation of plasma membrane long-chain fatty acid transport, positive regulation of blood coagulation, positive regulation of chemotaxis, proteoglycan binding, positive regulation of phosphorylation, chronic inflammatory response, collagen V binding, sprouting angiogenesis, glycoprotein binding, negative regulation of plasminogen activation, inflammatory response, positive regulation of tumor necrosis factor biosynthetic process, response to glucose stimulus, platelet alpha granule, positive regulation of fibroblast migration, positive regulation of angiogenesis, negative regulation of cell-matrix adhesion, positive regulation of blood vessel endothelial cell migration, positive regulation of protein kinase B signaling cascade, negative regulation of interleukin-12 production, positive regulation of macrophage activation, positive regulation of macrophage chemotaxis, fibronectin binding, platelet activation, negative regulation of endothelial cell proliferation, engulfment of apoptotic cell, negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II, fibrinogen binding, negative regulation of cGMP-mediated signaling, negative regulation of nitric oxide mediated signal transduction, negative regulation of dendritic cell antigen processing and presentation, platelet alpha granule lumen, low-density lipoprotein particle binding, positive regulation of reactive oxygen species metabolic process, positive regulation of transforming growth factor beta1 production
InterPro Term VWF_C, Laminin_G_thrombospondin_N, Thrombospondin_3-like_rpt, EGF_3, Thrombospondin_C, Thrombospondin_1_rpt, EGF-like, EGF-like_Ca-bd
UniProt Accession B4DDK8, P07996, A0PJG0, Q7KYY3, A8MZG1
Search EB-eye ENSG00000137801
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
HCC1143
2
E-MTAB-37, E-MTAB-62
HT1080
2
E-MTAB-37, E-GEOD-20089
K562
2
E-MTAB-37, E-GEOD-24147
KG1
2
E-MTAB-37, E-GEOD-24147
540 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (70 experiments)

Factor Value U/D Experiments
monocyte
1
4
E-GEOD-11755, E-GEOD-5099, E-MEXP-2019, E-GEOD-8286, E-GEOD-22373 ... (5 experiments)
stromal cell
1
4
E-GEOD-1460, E-MEXP-1121, E-MEXP-1327, E-GEOD-3998, E-GEOD-10797 ... (5 experiments)
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-MEXP-466
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
2
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
147 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, ... (89 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-MTAB-37, E-GEOD-3868 ... (5 experiments)
glioblastoma
1
4
E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4290, E-MEXP-567 ... (5 experiments)
dermatomyositis
3
E-MTAB-62, E-GEOD-1551, E-GEOD-5370
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-995
uterine fibroid
3
E-GEOD-7307, E-MTAB-62, E-GEOD-2724
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-4127
279 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-4668, E-GEOD-5741, E-GEOD-3720, ... (36 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
1
2
E-TABM-868, E-GEOD-3982, E-MEXP-1958
glutamine
1
E-MEXP-1335
valproic acid
1
E-GEOD-1615
-
1
1
E-MEXP-2645
ponasterone A
1
E-GEOD-3113
50 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
42 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-GEOD-22513, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (11 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, E-GEOD-4006, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-GEOD-837, ... (18 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-GEOD-5764, E-GEOD-1926, E-TABM-15, E-GEOD-3606, ... (49 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-461, E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-15811, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.348 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM